Switch theme
Sign up to access all valuation multiples
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution, to retain the quality of cryopreserved biomaterials.
2017
n/a
LTM Revenue n/a
LTM EBITDA n/a
$37.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vitrafy has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vitrafy achieved revenue of $23K and an EBITDA of $4K.
Vitrafy expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vitrafy valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $20K | $23K | n/a | XXX |
| Gross Profit | n/a | $20K | $23K | XXX | XXX |
| Gross Margin | NaN% | 100% | 100% | XXX | XXX |
| EBITDA | -$3.1M | -$1.8M | $4K | n/a | XXX |
| EBITDA Margin | NaN% | -8812% | 19% | NaN% | XXX |
| Net Profit | -$4.9M | -$5.0M | -$6.6M | XXX | XXX |
| Net Margin | NaN% | -24416% | -28176% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Vitrafy's stock price is AUD 1 (or $1).
Vitrafy has current market cap of AUD 92.4M (or $58.6M), and EV of AUD 58.4M (or $37.0M).
See Vitrafy trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $37.0M | $58.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Vitrafy has market cap of $58.6M and EV of $37.0M.
Vitrafy's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Vitrafy's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vitrafy and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $37.0M | XXX | XXX | XXX |
| EV/Revenue | 107.5x | XXX | XXX | XXX |
| EV/EBITDA | -7.8x | XXX | XXX | XXX |
| P/E | -5.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -5.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVitrafy's NTM/LTM revenue growth is Infinity%
Vitrafy's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Vitrafy's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vitrafy's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vitrafy and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1379% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -100% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7232% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11481% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 28935% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vitrafy acquired XXX companies to date.
Last acquisition by Vitrafy was XXXXXXXX, XXXXX XXXXX XXXXXX . Vitrafy acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vitrafy founded? | Vitrafy was founded in 2017. |
| Where is Vitrafy headquartered? | Vitrafy is headquartered in Australia. |
| Is Vitrafy publicy listed? | Yes, Vitrafy is a public company listed on ASX. |
| What is the stock symbol of Vitrafy? | Vitrafy trades under VFY ticker. |
| When did Vitrafy go public? | Vitrafy went public in 2024. |
| Who are competitors of Vitrafy? | Similar companies to Vitrafy include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Vitrafy? | Vitrafy's current market cap is $58.6M |
| What is the current revenue growth of Vitrafy? | Vitrafy revenue growth between 2023 and 2024 was 16%. |
| Is Vitrafy profitable? | Yes, Vitrafy is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
